IQ-AI Regulatory News (IQAI)

June 25, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics Opens Expanded Access Program

New cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma

Imaging Biometrics, LLC ("IB"), the Wisconsin USA based subsidiary of IQ-AI (LSE: IQAI), announces that the US Food and Drug Administration ("FDA") has approved an Expanded Access Program ("EAP") for oral gallium maltolate ("GaM").

This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin ("MCW"). As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP. Several patients have registered to participate in the EAP, and a total of 40 patients can enrol in this initial phase.

"Providing eligible patients access to GaM as a potential treatment ahead of regulatory approval underscores our commitment to helping address a clear unmet patient need," said Trevor Brown, CEO of IQAI.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.